Patents Assigned to Mallinckrodt Pharmaceuticals Ireland Limited
-
Patent number: 11950590Abstract: The present disclosure provides methods to improve the viability of an organ, or organs, by continuously administering a composition comprising NOx gas directly to the organ(s).Type: GrantFiled: June 28, 2021Date of Patent: April 9, 2024Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventor: Jim Potenziano
-
Patent number: 11918742Abstract: The present disclosure relates to a filter apparatus for filtering liquid from a gas, the apparatus having a first housing having a gas inlet and a gas outlet; a first filter media disposed in the first housing; a second filter media disposed in the housing; and a second housing forming a first collection basin disposed in the flow path between the first filter media and the second filter media, so that a path is defined for the gas flowing from the inlet, through the first filter media, past the collection basin, through the second filter media, and to the outlet. The present disclosure also relates to a method of passing a gas through a coalescing filter media and through a hydrophobic filter media.Type: GrantFiled: February 8, 2022Date of Patent: March 5, 2024Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Scott I. Biba, John Falligant
-
Patent number: 11833299Abstract: The present invention provides clinical decision support that can be used with non-portable and portable systems when delivering and/or monitoring delivery of a therapeutic gas comprising nitric oxide to a patient. Further, clinical decision support can be used with non-portable and portable systems during delivery and/or monitoring of delivery of therapeutic gas when nebulized drugs may and/or may not be being delivered to a patient (e.g., when nebulizers are delivered upstream in the inspiratory limb of the breathing circuit, into a breathing gas delivery system, etc.).Type: GrantFiled: November 7, 2019Date of Patent: December 5, 2023Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron Acker, Craig R. Tolmie
-
Patent number: 11759620Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.Type: GrantFiled: June 25, 2021Date of Patent: September 19, 2023Assignee: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITEDInventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan
-
Patent number: 11744976Abstract: A trap bowl is provided to accumulate liquid droplets from a filter, as a liquid content. The trap bowl includes a transparent vertical prism. The transparent vertical prism includes a face that forms a vertical transparent surface facing against a content of the section. The face can provide a first angle of total reflection when content of the section is a type of gas, and a second angle of total reflection when the content of the section is the liquid content. A light source may emit a light beam incident on the face at an angle of incidence. The angle of incidence results in reflection of the light beam, striking the light receiver, when the face has the first angle of total reflection, and results in refraction of the light beam, missing the light receiver, when the face has the second angle of total reflection.Type: GrantFiled: December 15, 2022Date of Patent: September 5, 2023Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventor: Scott I. Biba
-
Patent number: 11623054Abstract: Provided herein are systems and methods for delivery of therapeutic gas to patients, in need thereof, by receiving breathing gas from a high frequency ventilator using at least enhanced therapeutic gas (e.g., nitric oxide, NO, etc.) flow measurement. At least some of these enhanced therapeutic gas flow measurements can be used to address some surprising phenomenon that may, at times, occur when wild stream blending therapeutic gas into breathing gas a patient receives from a breathing circuit affiliated with a high frequency ventilator. Utilizing at least some of these enhanced therapeutic gas flow measurements the dose of therapeutic gas wild stream blended into breathing gas that the patient receives can at least be more accurate and/or under delivery of therapeutic gas into the breathing gas can be avoided and/or reduced.Type: GrantFiled: October 23, 2020Date of Patent: April 11, 2023Assignee: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITEDInventors: Jaron M. Acker, Craig R. Tolmie
-
Patent number: 11554235Abstract: A trap bowl is provided to accumulate liquid droplets from a filter, as a liquid content. The trap bowl includes a transparent vertical prism. The transparent vertical prism includes a face that forms a vertical transparent surface facing against a content of the section. The face can provide a first angle of total reflection when content of the section is a type of gas, and a second angle of total reflection when the content of the section is the liquid content. A light source may emit a light beam incident on the face at an angle of incidence. The angle of incidence results in reflection of the light beam, striking the light receiver, when the face has the first angle of total reflection, and results in refraction of the light beam, missing the light receiver, when the face has the second angle of total reflection.Type: GrantFiled: December 23, 2019Date of Patent: January 17, 2023Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventor: Scott I. Biba
-
Patent number: 11554242Abstract: The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a breakthrough of NO2, and providing an indication of the remaining useful life and/or breakthrough.Type: GrantFiled: July 3, 2019Date of Patent: January 17, 2023Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron M. Acker, Thomas Kohlmann
-
Patent number: 11529479Abstract: Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system.Type: GrantFiled: January 21, 2020Date of Patent: December 20, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron M. Acker, Jeff Milsap, Robin Roehl, Jeffrey Schmidt, Craig R. Tolmie
-
Patent number: 11471641Abstract: The present invention generally relates to systems and method for delivery of therapeutic gas to patients in need thereof using enhanced breathing circuit gas (BCG) flow measurement. At least some of these enhanced BCG flow measurements can be used to address some surprising phenomena that may, at times, occur when wild stream blending therapeutic gas into breathing gas that a patient receives from a breathing circuit affiliated with a ventilator. Utilizing at least some of these enhanced BCG flow measurements the dose of therapeutic gas wild stream blended into breathing gas that the patient receives from a ventilator can at least be more accurate and/or over delivery of therapeutic gas into the breathing gas can be avoided and/or reduced.Type: GrantFiled: January 22, 2019Date of Patent: October 18, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron M. Acker, Craig R. Tolmie
-
Patent number: 11474115Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.Type: GrantFiled: February 27, 2020Date of Patent: October 18, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
-
Patent number: 11452835Abstract: A therapeutic gas is administered to a patient. A sample gas is drawn from the therapeutic gas supply, and passed through a water-permeable tubular membrane. Concurrently, a section of the water permeable tubular membrane is maintained as a ventilated water permeable tubular membrane, by exposing outer surfaces of the ventilated water permeable tubular membrane to an ambient air flow. The ambient air flow may in some examples be moved over the tubular membrane via forced air such as for example via a fan associated with a housing surrounding the tubular membrane.Type: GrantFiled: October 28, 2019Date of Patent: September 27, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: John P. Stanton, John V. Berndt
-
Patent number: 11412731Abstract: Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.Type: GrantFiled: April 23, 2020Date of Patent: August 16, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jim Potenziano, Douglas R. Hansell, Jeff Griebel, Eddie Costa, Lisa Cooper, David William Newman
-
Patent number: 11324912Abstract: The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO2-to-NO reactor cartridge and/or a break-through of NO2, and providing an indication of the remaining useful life and/or break-through.Type: GrantFiled: November 26, 2019Date of Patent: May 10, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron Acker, Muhammad Asif, Craig Flanagan, Douglas Alan Greene, Sarah Jayne Ridley, Frank Kenneth Schweighardt, Lien-Lung Sheu
-
Patent number: 11291202Abstract: Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration.Type: GrantFiled: April 21, 2017Date of Patent: April 5, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jim Potenziano, Douglas R. Hansell, Jeff Griebel, Eddie Costa, Lisa Cooper, David William Newman
-
Patent number: 11291794Abstract: The present disclosure generally relates to systems and methods for delivery of therapeutic gas to patients, using techniques to compensate for disruptions in breathing gas flow measurement, such as when breathing gas flow measurement is unavailable or unreliable. Such techniques include using historical breathing gas flow rate data, such as moving average flow rates, moving median flow rates and/or flow waveforms. At least some of these techniques can be used to ensure that interruption in therapeutic gas delivery is minimized or eliminated.Type: GrantFiled: October 10, 2019Date of Patent: April 5, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron M. Acker, Craig R. Tolmie
-
Patent number: 11285280Abstract: Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system.Type: GrantFiled: March 20, 2020Date of Patent: March 29, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron M. Acker, Craig R. Tolmie, Robin Roehl, Jeffrey Schmidt, Jeff Milsap
-
Patent number: 11278696Abstract: The present disclosure relates to a filter apparatus for filtering liquid from a gas, the apparatus having a first housing having a gas inlet and a gas outlet; a first filter media disposed in the first housing; a second filter media disposed in the housing; and a second housing forming a first collection basin disposed in the flow path between the first filter media and the second filter media, so that a path is defined for the gas flowing from the inlet, through the first filter media, past the collection basin, through the second filter media, and to the outlet. The present disclosure also relates to a method of passing a gas through a coalescing filter media and through a hydrophobic filter media.Type: GrantFiled: May 1, 2020Date of Patent: March 22, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Scott I. Biba, John Falligant
-
Patent number: 11202873Abstract: Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system.Type: GrantFiled: December 5, 2019Date of Patent: December 21, 2021Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jaron M. Acker, John C. Falligant, Jeff Milsap, Robin Roehl, Jeffrey Schmidt, Craig R. Tolmie
-
Patent number: 11202899Abstract: Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.Type: GrantFiled: January 30, 2017Date of Patent: December 21, 2021Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Jim Potenziano, Douglas Alan Greene, Craig Flanagan